Healthcare
BioNTech Reports Revenue Plunge as Focus Shifts to Cancer Drugs
Shares Fall Over 9% as Biotech Giant Transitions Away from Pandemic-Era Vaccine Sales BioNTech (BNTX), the pioneering biotechnology firm behind...
AstraZeneca to Acquire Fusion Pharmaceuticals: Pioneering Precision Cancer Treatments
Acquisition Marks AstraZeneca's Commitment to Advancing Cancer Care with Radioconjugates AstraZeneca, (AZN) a leading global biopharmaceutical company, has announced a...
FDA Delays Decision on Eli Lilly’s Alzheimer’s Drug, Donanemab
Eli Lilly's anticipation for the Food and Drug Administration's approval decision regarding its Alzheimer's treatment, donanemab, faces a setback as...
Vivani Medical Unveils Promising Preclinical Data on Weight Loss Implants
Vivani Medical (VANI) released preclinical data on weight loss effects for NPM-115 Vivani Medical (VANI) on Wednesday, unveiled preclinical findings...
Janux Therapeutics Unveils Promising Updates on Cancer Treatments
Janux Therapeutics Inc (JANX) disclosed updated findings on its experimental drugs, JANX007 and JANX008, showcasing significant progress in treating metastatic...
Ocular Therapeutix Announces Private Placement to Bolster Clinical Development Initiatives
Ocular Therapeutix, Inc. (OCUL), a pioneering biopharmaceutical company dedicated to advancing vision-related therapies, has disclosed its strategic move to enhance...
Monopar’s MNPR-101 Radiopharma Program Shows Promise in Targeting Advanced Cancers
Monopar Therapeutics (MNPR) has unveiled promising preclinical data for its MNPR-101 radiopharmaceutical program, marking a significant stride in the fight...
Moderna Reports Strong Spikevax Sales and Expands Vaccine Portfolio
Moderna Inc (MRNA) witnessed a surge in its stock following its fourth-quarter 2023 financial report, which showcased robust revenues of...
AbbVie Plans $13 Billion Bond Sale for Acquisitions
According to Bloomberg News sources familiar with the matter, AbbVie is gearing up to sell a minimum of $13 billion...
Bausch + Lomb’s Strong Growth Outlook Boosts Stock Amid Losses
Bausch + Lomb Corp (BLCO) experienced a significant surge in its stock value, rising by 15.8%, despite facing deeper losses,...
